



Canadian Cardiovascular Society Contemporary Management of the Patient with Hypertrophic Cardiomyopathy Clinical Practice Guideline

Panel Member Disclosures
July, 2024

The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Updated March 8, 2023.

Affiliations with commercial organizations or clinical trials within the previous two years that may have a direct or indirect connection to the content of this statement are disclosed here.

Members		Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
Panel members					
Primary Panel					
First name	Last name				
Rafik	Tadros	None	Bristol-Myers Squibb (BMS)	None	BMS produce Mavacamten. Received research support from BMS. Provided consultation to BMS with consulting fees paid to institution (not individual).
Andrew	Crean	None	None	None	BMS affiliation could give rise to perceived conflict given that they manufacture mavacamten which is mentioned in the document. However reference to alternative myosin inhibitors is also briefly made even though they are not yet clinically available.
Arnon	Adler	Bristol-Myers Squibb (BMS) Bristol-Myers Squibb	None	None	BMS produce Mavacamten
Zachary	Laksman	Abbott Canada, Bayer, BMS Pfizer, Boston Scientific, Medtronic, Servier	None	None	I do not foresee a conflict with previous fees/honoraria and the CPU - should any arise I will contact either the CPU leads or the CCS as appropriate
Colette	Seifer	None	None	None	None
Kevin	Ong	Bristol-Myers Squibb	None	None	Provided consultation to BMS regarding Mavacamten, a novel myosin inhibitor developed to treat obstructive HCM.
Marc	Ruel	Medtronic	Medtronic	None	Proctor, MICS CABG
Robert	Cooper	Bristol-Myers Squibb, Pfizer	None	None	These specific honoraria do not link to my contribution to this guideline. They represent payments given to teach and provide consultation not linked to my contribution
Bobby	Heydari	Bristol-Myers Squibb	Bristol-Myers Squibb	None	I have received funding from BMS for educational talks related to hypertrophic cardiomyopathy.
Genevieve	Girardeau	BMS Pfizer, Novartis, Pfizer	Bristol-Myers Squibb	None	Consulting: no relation with this guideline Clinical Trial: PI for Mavacamten: ODYSSEY study
Seema	Mital	Bristol-Myers Squibb, Tenaya Therapeutics, Rocket Pharmaceuticals	Site co-investigator, SCOUT-HCM, pediatric trial of mavacamten (BMS sponsored)	None	All 3 companies are developing and/or trialing therapies for HCM
Laura Susan	Arbour Christian	None	None	None	None
Patrick	Garceau	Abbott Canada, Bristol-Myers Squibb	Abbott Canada, Medtronic	None	Lecturing and advisory board participation; no conflict
Michael	Ward	Bristol-Myers Squibb	Bristol-Myers Squibb	None	Ad Board for BMS and Mavacamten use
Chris	Overgaard	None	None	None	Local PI for trials
Joyce	Chan	None	None	None	None